Drugs / Non-adjuvanted HSV formulation 3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05298254 | Mar 2022 → Jun 2025 | herpes simplex infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Non-adjuvanted HSV formulation 3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05298254 ↗ |
| Modality | Vaccine | “non-adjuvanted HSV formulation 3 vaccine” NCT05298254 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT05298254 ↗ |